PROGRESS - 医索

2020ASCO——晚期NSCLC免疫治疗篇(中)

编译：李峻岭来源：医科院肿瘤医院李峻岭医生李峻岭教授带来2020 ASCO晚期非小细胞肺癌免疫治疗研究进展解读。摘要号9547Circulating and tumor-associated neutrophil subtypes discriminate hyper progressive diseas.....

学术资讯 - 临床医学

览临床进展更新，品学术交流之乐 | 辉耀生命- 2020 ASCO会后会大幕即将开启

2020年5月29日—31日，一年一度的美国临床肿瘤学会（ASCO）年会首次以线上虚拟会议形式召开，以别样的方式传递肿瘤学最新进展。本届年会的主题是“Unite & Conquer: Accelerating Progress Together”。为了满足中国广大肿瘤领域专家学术.....

学术资讯 - 临床医学

ELSA Study ：Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA)， a randomized， double

Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclero.....

学术资讯 - 临床研究

SOLVD：Effects of the angiotensin converting enzyme inhibitor enalapril on the long

Circulation. 1992 Aug;86(2):431-8. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators......

学术资讯 - 临床研究

REVERSAL Trial：Effect of intensive compared with moderate lipid

JAMA. 2004 Mar 3;291(9):1071-80. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. [REVERSAL] Nissen SE， Tuzcu EM， Schoenhagen .....

学术资讯 - 临床研究

IDNT：The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes. (IDNT)

Lewis EJ. Department of Nephrology， Rush-Presbyterian-St. Luke’s Medical Center， Chicago， Illinois 60612， USA. Diabetes mellitus is the most common cause.....

学术资讯 - 临床研究

ELSA Trial.：Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA)， a randomized， double

Circulation. 2002 Nov 5;106(19):2422-7. Zanchetti A， Bond MG， Hennig M， Neiss A， Manc.....

学术资讯 - 临床研究

2020ASCO——晚期NSCLC免疫治疗篇(中)

览临床进展更新，品学术交流之乐 | 辉耀生命- 2020 ASCO会后会大幕即将开启

ELSA Study ：Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA)， a randomized， double

SOLVD：Effects of the angiotensin converting enzyme inhibitor enalapril on the long

REVERSAL Trial：Effect of intensive compared with moderate lipid

IDNT：The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes. (IDNT)

ELSA Trial.：Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA)， a randomized， double

代谢综合征患者主动脉狭窄进展更快

β受体阻滞剂治疗能减缓冠状动脉疾病的进展：4个血管内超声试验的汇总分析

冠状动脉钙化具备遗传性